Ergoteles’s Cytokinetics CYTK Stock Holding History

Ergoteles’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,020	Closed	-$388K	–	1131
2023 Q1	$388K	Sell	11,020 -24,016	-69%	-$980K	0.02%	824
2022 Q4	$1.61M	Buy	+35,036	New	+$1.51M	0.06%	329
2022 Q1	–	Sell	-47,841	Closed	-$2.18M	–	1300
2021 Q4	$2.18M	Buy	+47,841	New	+$1.85M	0.08%	241

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ergoteles's CYTK Position: Q2 2023 in Review

Ergoteles sold out of Cytokinetics (CYTK) in Q2 2023, closing a stake of 11,020 shares — an estimated $388K sold.

Ergoteles first reported a position in CYTK in Q4 2021 and held it in 3 quarters. The position peaked at $2.18M in Q4 2021. 253 funds tracked by Wall St. Rank hold CYTK as of Q2 2023.

Ergoteles reported no remaining Cytokinetics position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 11,020 Cytokinetics shares in Q2 2023, an estimated $388K.
Ergoteles first reported a position in Cytokinetics in Q4 2021 and held it in 3 quarters.
Ergoteles's Cytokinetics position peaked at $2.18M in Q4 2021.
253 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.